Document is current

Article History

Received: 31 July 2024

Accepted: 4 September 2024

First Online: 17 September 2024

Declarations

:

: Brian J. Burkett Research Support- GE Healthcare and the Radiological Society of North America. Derek R. Johnson Consulting or Advisory Role- Telix. Geoffrey B. Johnson Leadership—Green Clinic (I); Nucleus RadioPharma (Inst) Consulting or Advisory Role—AstraZeneca (Inst); Blue Earth Diagnostics (Inst); Curium Pharma (Inst); MedTrace (Inst); MorphImmune (Inst); Novartis (Inst); Siemens Healthineers (Inst); Viewpoint Molecular Targeting (Inst); Viewpoint Molecular Targeting (Inst); Z-Alpha (Inst) Research Funding—Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); MedTrace (Inst); Novartis (Inst); Pfizer (Inst); Viewpoint Molecular Targeting (Inst); Viewpoint Molecular Targeting (Inst) Patents, Royalties, Other Intellectual Property—Patents on Radiopharmaceuticals; Patents on Radiopharmaceuticals (Inst). David F. Kallmes holds equity in Nested Knowledge, Superior Medical Experts, and Conway Medical, Marblehead Medical, and Piraeus Medical; he received grant support from Microvention, Medtronic, Neurogami, Cerenovus, Brainomix, MIVI Neurosciences, Stryker, Balt, and Insera Therapeutics; has served on the Data Safety Monitoring Board for Vesalio and NoNo Inc.; and received royalties from Medtronic. Oliver Sartor Stock and Other Ownership Interests—Abbvie; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Fusion Pharmaceuticals; Lilly; Ratiopharm; Telix Pharmaceuticals; United Health Group Honoraria—Lantheus Medical Imaging Consulting or Advisory Role—Advanced Accelerator Applications; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Fusion Pharmaceuticals; Hengrui Therapeutics; Isotopen Technologien; Janssen; MacroGenics; Medscape; Merck; Northstar; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Ratio; Sanofi; Telix Pharmaceuticals; Tempus; TeneoBio; Tessa Therapeutics Research Funding—Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); point Biopharma; Progenics (Inst); Sanofi (Inst); Patents, Royalties, Other Intellectual Property—Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691). Expert Testimony—Sanofi Travel, Accommodations, Expenses—AstraZeneca; Bayer; Johnson & Johnson; Lantheus Medical Imaging; Progenics; Sanofi Ayse T. Kendi Consulting or Advisory Role—Novartis Research Funding—Novartis (Inst).